Bristol Myers Squibb (NYSE:BMY) Announces Quarterly Earnings Results

Bristol Myers Squibb (NYSE:BMY) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44, FiscalAI reports. The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period last year, the firm earned $1.46 EPS. Bristol Myers Squibb updated its FY 2026 guidance to 6.750-7.000 EPS.

Here are the key takeaways from Bristol Myers Squibb’s conference call:

• Second-quarter results exceeded expectations: Revenue increased 5% to approximately $13 billion, with the growth portfolio up 14% to $7.6 billion and adjusted EPS of $2.04. Management raised its full-year 2026 revenue and adjusted EPS guidance.
• Growth was broad-based, led by ELIQUIS demand growth of 21%, BREYANZI growth of 41%, CAMZYOS growth of 59%, REBLOZYL growth of 29%, and continued momentum for Sotyktu and Opdivo Qvantig. Management now expects ELIQUIS revenue growth of 20%-25% for 2026.
• The company highlighted multiple potential pipeline catalysts, including late-2026 readouts for amilparant, Sotyktu in lupus, milvexian in secondary stroke prevention, and several oncology programs. Iberdomide’s FDA decision is expected August 17, 2026, while mezigdomide has a May 2027 PDUFA date.
• Timelines for important studies have moved later: milvexian’s atrial-fibrillation readout is now expected in the first quarter of 2027, while COBENFY’s ADEPT program readouts will begin in early 2027 and extend through the year. Management attributed the delays to slower event accrual and efforts to preserve study quality, while maintaining confidence in the programs.
• Bristol Myers Squibb reported approximately $3.4 billion in second-quarter operating cash flow, $11.5 billion in cash and marketable securities, and another $1.2 billion of debt repayment. Productivity savings and financial flexibility are supporting continued pipeline investment, potential business development, and shareholder returns.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY traded up $1.88 on Thursday, reaching $64.98. The company’s stock had a trading volume of 18,018,696 shares, compared to its average volume of 12,268,565. Bristol Myers Squibb has a 52-week low of $42.52 and a 52-week high of $65.56. The company has a market cap of $132.70 billion, a P/E ratio of 18.25, a PEG ratio of 0.18 and a beta of 0.23. The company has a 50-day simple moving average of $57.90 and a 200 day simple moving average of $58.29. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 70.79%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Brighton Jones LLC raised its position in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the period. Sivia Capital Partners LLC grew its holdings in Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 2,786 shares during the period. Gilpin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $102,000. Prosperity Bancshares Inc purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $84,000. Finally, Binnacle Investments Inc grew its stake in Bristol Myers Squibb by 17.0% in the 2nd quarter. Binnacle Investments Inc now owns 1,801 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 262 shares during the period. Institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Cantor Fitzgerald reiterated a “neutral” rating and set a $54.00 price target on shares of Bristol Myers Squibb in a report on Monday, July 6th. Weiss Ratings cut shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, July 16th. Raymond James Financial reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday. Finally, Guggenheim restated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $61.25.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Quarterly results exceeded expectations. BMY reported adjusted earnings of $2.04 per share versus the $1.60 consensus estimate, while revenue rose 5.7% year over year to $12.97 billion, well ahead of the $11.74 billion forecast. Earnings also increased from $1.46 per share in the prior-year quarter. Reuters article
• Positive Sentiment: Management raised its 2026 outlook. The company now expects adjusted EPS of $6.75–$7.00 and revenue of $49 billion–$50 billion, above analyst expectations of approximately $6.31 EPS and $47.3 billion in revenue. Wall Street Journal article
• Positive Sentiment: Growth products are helping offset patent-related pressure. Strong demand for Eliquis, along with newer treatments including Camzyos, Reblozyl, Opdivo Qvantig and Breyanzi, supported the quarter. Investors are increasingly focused on whether these products can replace declining legacy-drug revenue. Quartz article
• Positive Sentiment: Valuation remains attractive to some analysts. A bullish view highlighted BMY’s low forward valuation and roughly 4% dividend yield, while Piper Sandler maintained a Buy rating. Seeking Alpha article
• Neutral Sentiment: Analyst opinion remains mixed: strong results and a better Eliquis outlook were balanced by a Hold rating reflecting legacy-product declines and delays or uneven performance among pipeline assets. TipRanks article
• Negative Sentiment: Put-option trading was unusually heavy, with 44,620 puts purchased—about 77% above average—signaling that some traders are hedging against a pullback or taking a bearish view despite the earnings beat.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.